

Professor PN Hawkins PhD FRCP FRCPATH FMedSci
Tel: 020 7433 2815 (PA 2816) Email: p.hawkins@ucl.ac.uk
Dr JD Gillmore MD PhD FRCP
Tel: 020 7433 2726 Email: j.gillmore@ucl.ac.uk
Dr HJ Lachmann MD FRCP
Tel: 020 7433 2804 Email: h.lachmann@ucl.ac.uk
Dr AD Wechalekar MD FRCP FRCPATH
Tel: 020 7433 2758 Email: a.wechalekar@ucl.ac.uk
Dr CJ Whelan MD MRCP
Tel: 020 7433 2875 Email: c.whelan@ucl.ac.uk

General Enquiries Tel: 020 7433 2725
Clinical Secretaries Tel: 020 7433 2811/2798/2772
Pathology Coordinator Tel: 020 7433 2753
Fax: ++44 (0)20 7433 2817

Full dose Cyclophosphamide-Bortezomib-Dexamethasone protocol (21 day cycle)

This protocol is for patients with Mayo Stage I and selected stage II

Please see intermediate dose protocol for stage II/Early stage III patients and low dose protocol for Advanced stage III

	Day 1	Day 4	Day 8	Day 11	Day 15
Bortezomib 1.3mg/m ² sc	*	*	*	*	
Cyclophosphamide 350mg/m ² PO (max 500mg) ^b	*		*		*
Dexamethasone 20mg PO/IV ^c	*	*	*	*	

^a Use bortezomib IV if there is marked abdominal wall oedema due to uncertain absorption from oedematous sites

^b Dose modify in renal failure (if eGFR <30 ml/min, reduce to 250 mg/m² or as per local guidelines)

^c Dexamethasone should be given as 20 mg on day 1 of cycle 1 and depending on tolerance should be increased to 20 mg on days 1,2, 4,5,8,9,11,12 (or 40 mg on Day 1, 4, 8, 11)

The cycle is repeated every 21 days

- All patients will receive a minimum of three cycles of CVD in the absence of unacceptable toxicity or poor tolerability.
- Response should be assessed at the end of each cycle:
 - Patients who achieve a complete response or VGPR will continue for one more cycle after achieving response (e.g. if patient has achieved CR or VGPR at cycle 1 or 2, they will finish three cycles and stop. If they achieve CR or plateau after cycle 3, they will receive one more cycle after achieving CR or plateau).
 - Patients with ongoing reduction in dFLC should continue until they achieve VGPR or complete response or to a maximum of 8 cycles.
 - Patients who have not responded to treatment by end of cycle 2 will need regime modification after discussion with the NAC or as per local practice.

Prophylactic Medicines

All patients should receive prophylaxis as per local guidance or as suggested below:

- Oral acyclovir 400 mg twice daily with **dose modified according to renal function** or appropriate alternative. Acyclovir should be continued for three months after the last dose of bortezomib.
- Oral Lansoprazole 15 mg once daily or Omeprazole 20mg once daily or appropriate alternative
- Oral Co-trimoxazole 480 mg twice daily given three times weekly (unless contraindicated).

National Amyloidosis Centre, UCL Division of Medicine, Royal Free London, Rowland Hill Street, London NW3 2PF. UK

www.ucl.ac.uk/amyloidosis

Prophylaxis to be continued for the duration of chemotherapy.

Antiemetics should be administered as per local protocols.